

One aspect relates to the use of Compound A:



(A),

or a pharmaceutically acceptable salt or solvate thereof for preparing a medicament for treating, preventing, or managing lymphoma or leukemia, wherein the Compound A is to be administered in combination with obinutuzumab, and wherein said Compound A is to be administered simultaneously, separately or sequentially with obinutuzumab.

Another aspect concerns the use of Compound A:




(A),

or a pharmaceutically acceptable salt or solvate thereof, in combination with obinutuzumab, or a pharmaceutically acceptable salt or solvate thereof, for preparing a medicament for treating, preventing, or managing lymphoma or leukemia, wherein said Compound A is to be administered simultaneously, separately or sequentially with obinutuzumab of a pharmaceutically acceptable salt or solvate thereof.

CLAIMS


1. Use of Compound A:



(A),

or a pharmaceutically acceptable salt or solvate thereoffor preparing a medicament for treating, preventing, or managing lymphoma or leukemia, wherein the Compound A is to be administered in combination with obinutuzumab; and wherein said Compound A is to be administered simultaneously, separately or sequentially with obinutuzumab.

2. Use of Compound A:



(A),

or a pharmaceutically acceptable salt or solvate thereof, in combination with obinutuzumab, or a pharmaceutically acceptable salt or solvate thereof, for preparing a medicament for treating, preventing, or managing lymphoma or leukemia, wherein said Compound A is to be administered simultaneously, separately or sequentially with obinutuzumab or a pharmaceutically acceptable salt or solvate thereof.

3. Use of claims 1 or 2, wherein said lymphoma is diffuse large B-cell lymphoma (DLBCL).